Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 1.9% - Still a Buy?

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) rose 1.9% on Thursday . The company traded as high as $5.78 and last traded at $5.69. Approximately 4,126,428 shares traded hands during trading, a decline of 66% from the average daily volume of 12,161,440 shares. The stock had previously closed at $5.58.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Morgan Stanley reduced their price objective on shares of Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating for the company in a research note on Thursday, April 10th. KeyCorp cut their target price on Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating for the company in a research note on Wednesday, January 8th. Leerink Partners lowered their target price on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a research note on Friday, February 28th. Cowen restated a "hold" rating on shares of Recursion Pharmaceuticals in a research report on Friday, February 28th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $11.00 price objective on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 8th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $8.20.

Recursion Pharmaceuticals Stock Performance

The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. The company's 50-day moving average price is $6.40 and its 200 day moving average price is $6.78. The stock has a market capitalization of $2.28 billion, a PE ratio of -3.72 and a beta of 1.00.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its earnings results on Friday, February 28th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The firm had revenue of $4.60 million during the quarter, compared to the consensus estimate of $19.04 million. During the same period in the prior year, the company posted ($0.42) EPS. The firm's revenue was down 57.8% on a year-over-year basis. On average, equities research analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of RXRX. Ensign Peak Advisors Inc boosted its position in shares of Recursion Pharmaceuticals by 0.3% in the 4th quarter. Ensign Peak Advisors Inc now owns 410,286 shares of the company's stock worth $2,774,000 after purchasing an additional 1,300 shares in the last quarter. Farther Finance Advisors LLC raised its position in shares of Recursion Pharmaceuticals by 21.1% in the 4th quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company's stock worth $52,000 after purchasing an additional 1,353 shares during the last quarter. Summit Investment Advisors Inc. grew its position in Recursion Pharmaceuticals by 7.8% during the 4th quarter. Summit Investment Advisors Inc. now owns 26,030 shares of the company's stock valued at $176,000 after purchasing an additional 1,875 shares during the last quarter. Wedmont Private Capital increased its stake in Recursion Pharmaceuticals by 10.6% during the 4th quarter. Wedmont Private Capital now owns 20,943 shares of the company's stock valued at $144,000 after purchasing an additional 2,000 shares in the last quarter. Finally, GAMMA Investing LLC raised its holdings in Recursion Pharmaceuticals by 39.0% in the first quarter. GAMMA Investing LLC now owns 7,224 shares of the company's stock worth $38,000 after buying an additional 2,026 shares during the last quarter. 89.06% of the stock is currently owned by institutional investors.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.